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Mitochondrial haplogroups are 
not associated with diabetic 
retinopathy in a large Australian 
and British Caucasian sample
Ebony Liu1, Georgia Kaidonis1, Mark C. Gillies2, Sotoodeh Abhary1, Rohan W. Essex  3,  
John H. Chang4,5, Bishwanath Pal5, Mark Daniell6, Stewart Lake1, Jolly Gilhotra7, 
Nikolai Petrovsky  8, Alex W. Hewitt  9, Alicia Jenkins10, Ecosse L. Lamoureux9,13, 
Jonathan M. Gleadle  11, Kathryn P. Burdon  1,12 & Jamie E. Craig1
Mitochondrial haplogroups H1, H2 and UK have previously been reported to be associated with 
proliferative diabetic retinopathy (PDR) in Caucasian patients with diabetes. We aimed to replicate 
this finding with a larger sample and expand the analysis to include different severities of DR, and 
diabetic macular edema (DME). Caucasian participants (n = 2935) with either type 1 or type 2 diabetes 
from the Australian Registry of Advanced Diabetic Retinopathy were enrolled in this study. Twenty-
two mitochondrial single nucleotide polymorphisms were genotyped by MassArray and haplogroups 
reconstructed using Haplogrep. Chi square tests and logistic regressions were used to test associations 
between haplogroup and DR phenotypes including any DR, non-proliferative DR (NPDR), proliferative 
DR (PDR) and DME. After stratifying the samples in type 1 and type 2 diabetes groups, and adjusting for 
sex, age, diabetes duration, concurrent HbA1c and hypertension, neither haplogroups H1, H2, UK, K or 
JT were associated with any DR, NPDR, PDR or DME.
Diabetic retinopathy (DR) is a leading cause of vision loss from diabetes driven damage to the retina. It is becom-
ing increasingly prevalent in spite of better risk factor control and screening1. Globally, from 1990 to 2010, visual 
impairment attributable to diabetes increased by 64% from 2.3 million to 3.7 million2. Vision loss occurs from 
proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME). PDR is the most severe form of DR 
and is characterized by the growth of pathological vessels in the retina. DME can occur at any stage of DR and is 
characterized by oedema in the macula region of the retina.
DR has a complex genetic component3. While several studies have explored genes involved in inflammation 
and angiogenesis related pathways (such as vascular endothelial growth factor), little research has focused on the 
role of mitochondrial DNA (mtDNA) in the susceptibility of DR4,5. It is well established that oxidative stress plays 
a key role in the pathogenesis of diabetic complications, including DR6. A significant source of reactive oxygen 
species (ROS) is from the mitochondria. Mitochondrial overproduction of ROS is hypothesized to be the single 
upstream event that mediates multiple mechanisms of hyperglycemia induced damage to tissues including polyol 
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pathway flux, increased formation of advanced glycation end products (AGEs), increased expression of AGE recep-
tors and activating ligands, activation of protein kinase C isoforms and overactivity of the hexosamine pathway7. 
Furthermore, mtDNA is highly sensitive to oxidative damage and has a high mutation rate with implications for 
electron transport chain function and endothelial cell survival, even long after the initial hyperglycemic insult8–10.
A common classification system for mtDNA variation is mitochondrial haplogroup, which represents the 
major branch points on the mitochondrial phylogenetic tree of human evolution. Estopinal et al. reported that 
haplogroups H1, H2 and UK in a Caucasian sample (n = 392) were associated with PDR11. Haplogroup H1 and 
H2 were risk factors for the development of PDR from non-proliferative diabetic retinopathy (NPDR), while hap-
logroup UK was protective against PDR. Subsequently, Bregman et al. reported similar findings in a larger group 
from the same population (n = 637), and reported further that while mitochondrial haplogroup was associated 
with PDR, it was not associated with DR more generally12. A different case control study (149 with any type of DR 
and 78 with no DR) found a higher prevalence of haplogroup T in those with any DR (12.1% vs 5.1%; p = 0.046)13.
We sought to replicate these studies in a larger sample (n = 2935) with increased power to explore other DR 
phenotypes such as DME and to evaluate this association in participants with type 1 and type 2 diabetes mellitus.
Methods
Ethics statement. This project has been approved by the human research ethics committees (HRECs) in 
Australia (Southern Adelaide Clinical HREC, Royal Adelaide Hospital HREC, The Queen Elizabeth Hospital 
HREC, Royal Melbourne Hospital HREC, Royal Victorian Eye and Ear Hospital HREC, St. Vincent’s Hospital 
(Melbourne) HREC, South Eastern Sydney Illawarra HREC, Tasmania Health and Medical HREC) and the NHS 
Health Research Authority in London. It adheres to the tenets of the Declaration of Helsinki. Written informed 
consent was obtained from each participant before study enrolment.
Recruitment of patients and data collection. This study was carried out among Caucasian partici-
pants (identifying as of European descent) recruited in the Australian Registry of Advanced Diabetic Retinopathy 
(RADAR) and the Genetic Study of Diabetic Retinopathy based at Flinders University, South Australia. Multiple 
recruitment centres were involved and included the following Australian hospitals; Flinders Medical Centre, The 
Repatriation General Hospital, The Royal Adelaide Hospital, The Queen Elizabeth Hospital, The Royal Melbourne 
Hospital, Royal Victorian Eye and Ear Hospital, St. Vincent’s Hospital, Sydney Eye Hospital, Canberra Hospital, 
Royal Hobart Hospital, and from the United Kingdom; The National Institute for Health Research Biomedical 
Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, 
London, United Kingdom.
Eligible participants were actively recruited from ophthalmology, diabetes and renal clinics, with the following 
inclusion criteria: 1) type 1 (T1DM) or type 2 diabetes mellitus (T2DM). Those with T2DM must have received at 
least 5 years of medical treatment for diabetes (oral hypoglycemic agents or insulin) prior to enrolment, and must 
have been over 18 years of age. All participants underwent a questionnaire and venous blood sample collection for 
DNA analysis. Clinical information was collected from case notes and electronic records, including the average 
of three most recent, available HbA1c measurements (or three measurements immediately prior to a diagnosis of 
PDR), renal and lipid measures, medications and the presence of non-ocular diabetic complications. DR grading 
(defined as the worst ever grading) and the presence of DME were determined from documented dilated fundus 
exams performed by an ophthalmologist. DR grading was defined by the International Clinical DR Severity Scale14. 
Clinically significant macula edema (CSME) was defined according to the Early Treatment Diabetic Retinopathy 
Study protocol: 1) retinal thickening within 500 μm of the center of the macula, 2) hard exudates at or within 500 μm 
of the centre of the macular if associated with thickening of the adjacent retina or 3) retinal thickening 1 disc area in 
size, within 1 disc diameter of the centre15. Sight threatening DR was defined as either severe NPDR, PDR or CSME.
For each participant, approximately 8 mL of blood was collected in EDTA blood collection tubes and under-
went DNA extraction using the QIAamp Blood DNA Maxi Kits (Qiagen, Venlo, The Netherlands). More detail 
regarding the data collection method has been described previously16.
Genotyping and mitochondrial haplogroup determination. Genotyping was performed through the 
Australian Genome Research Facility (AGRF), using the Agena Bioscience MassARRAY platform. We utilized the 
same panel of 22 mtDNA SNPs designed by Estopinal et al. in previous studies to determine mitochondrial hap-
logroup (Supplementary Table 1)11. Haplogrep software was used to facilitate haplogroup identification17. Samples 
identified as non-Caucasian after haplogroup determination were removed from the analyses.
Statistical analyses. Statistical analysis was performed with Statistical Package for Social Sciences versions 
23.0 (For Windows; IBM Corp, Armonk, NY). Chi Square tests were performed to analyse the association of hap-
logroup type with various DR phenotypes such as any DR, any NPDR, PDR, DME and CSME. Logistic regression 
was used to adjust for covariates age, sex, type of diabetes, duration of diabetes, HbA1c and presence of hyperten-
sion. Statistical significance was taken at p < 0.05. Further analysis was performed by stratifying the analysis into 
T1DM and T2DM cohorts, and the major European haplogroups (H1 and H2, UK).
Results
Patient demographics (n = 2935) stratified by DR phenotype are presented in Table 1. Chi square tests and 
Mann-Whitney U tests were used to compare demographic variables between the different phenotype groups 
(Table 2). Diabetes duration, HbA1c and hypertension were associated with all subtypes of DR and DME. 
Diabetes duration and HbA1c significantly increased from no DR to NPDR, PDR, DME or CSME(p < 0.0001, 
Mann-Whitney U test) and similarly from NPDR to PDR. Type of diabetes was also a significant variable affecting 
DR phenotypes PDR, any DME and CSME. Participants with PDR were younger than those with NPDR (median 
59 versus 64 years, p < 0.0001).
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Mitochondria haplogroup and DR phenotype. A total of 7 European mitochondrial haplogroups were 
identified in our Caucasian sample. The most common ones were haplogroup H1 and H2 (analysed collectively) 
and UK at 50.8% and 22.5% respectively. Other types included JT (12.4%), R (7.1%), I (4.2%), W (2.0%) and X 
(1.0%) (Supplementary Table 2). One SNP (rs3088053, rCRS position 11812) failed genotyping and therefore 
Haplogroup T2 could not be identified in our samples. As T2 is a subtype of J, we have therefore combined hap-
logroups J, T1 (and T2) in our analyses.
We found the percentages of the three most common haplotype groups (H1 and H2, UK and JT) were dis-
tributed similarly in each of the different phenotype groups, and that any differences when compared with no DR 
controls were not statistically significant after performing Chi Square association tests (Table 3). We also found 
no significant associations when haplogroups were compared between NPDR and PDR. There were no significant 
differences when all 7 haplogroups were analysed separately instead of grouping less common haplogroups into 
one category.
After separating the samples per diabetes type, the majority were T2DM participants (n = 2265) com-
pared with T1DM participants (n = 670). The demographics of the T1DM and T2DM groups are given in 
Supplementary Tables 3 and 5 respectively. P values comparing the demographic variables between cases and 
controls in the T1DM and T2DM groups are given in Supplementary Table 5 and 6 respectively. Duration of 
diabetes, HbA1c and the presence of hypertension were significantly increased from no DR to NPDR, PDR, DME 
or CSME (p < 0.01, Mann-Whitney U test) and similarly from NPDR to PDR in both types of diabetes. Binary 
logistic regression show that haplogroups H1 and H2, and UK were not associated with any DR phenotypes in 
either T1DM or T2DM after adjustment for sex, age, diabetes duration, HbA1c and hypertension (Tables 4 and 5). 
After logistic regression, diabetes duration and HbA1c remain significant risk factors for DR in both type 1 and 
type 2 diabetes, while hypertension only remained significant in type 1 diabetes.
The next most common haplogroups (JT and K separately from UK) were analysed separately (frequencies 12.4% 
and 7.8% respectively). Significant results were: haplogroup K was nominally associated with any DR (135 cases, 
Demographic Total No DR Any DR Any NPDR PDR Any DME CSME Sight threatening
n 2935 1124 1811 1161 650 936 643 1278
Female; n (%) 1309 (44.6) 521 (46.5) 788 (43.7) 514 (44.4) 274 (42.4) 420 (45.5) 289 (45.2) 558 (43.9)
Age in yrs; median (range) 61 (17–95) 65 (17–95) 63 (18–95) 65 (18–95) 59 (21–90) 65 (21–92) 65 (26–92) 63 (21–92)
Diabetes duration in yrs; median (range) 18 (5–70) 12 (5–67) 20 (5–70) 18 (5–65) 23 (5–70) 19 (5–64) 19 (5–59) 20 (5–70)
Type 1 diabetes; n (%) 670 (22.8) 239 (21.5) 431 (24.1) 208 (18.2) 223 (34.6) 148 (16.0) 100 (15.7) 297 (23.5)
HbA1c %; median (range) 8.07 (2–22) 7.40 (2–22) 8.10 (4–15) 7.90 (5–15) 8.50 (4–15) 8.20 (4–15) 8.10 (5–15) 8.25 (4–15)
Hypertension; n (%) 1935 (65.9) 695 (61.8) 1240 (68.5) 782 (67.4) 458 (70.5) 642 (68.6) 471 (73.3) 874 (68.4)
Table 1. Demographics of study population stratified by diabetic retinopathy phenotype.
No DR vs 
any DR
No DR vs 
any NPDR
No DR vs 
PDR
No DR vs 
DME
No DR vs 
CSME
No DR vs Sight 
threatening
Sex 0.077 0.333 0.102 0.563 0.619 0.216
Age 0.103 0.190 <0.0001 0.761 0.848 0.041
Diabetes duration <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Diabetes type 0.103 0.051 <0.0001 1.79 × 10−3 3.79 × 10−3 0.258
HbA1c <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Hypertension 3.74 × 10−4 2.91 × 10−3 1.18 × 10−3 2.36 × 10−3 <0.0001 1.37 × 10−3
Table 2. P values of demographic variables compared between the DR phenotype groups.
Haplogroup
Proportion (%) P value (Chi Square tests) 
comparison to controls (No DR)H UK JT I, R,W,X
No DR 50.7 22.5 12.2 14.6 NA
Any DR 50.4 22.9 12.9 13.8 0.885
NPDR 50.9 22.9 12.4 13.8 0.954
PDR 49.5 22.8 13.8 13.8 0.760
DME 51.0 23.3 12.5 13.2 0.830
CSME 49.6 23.3 13.2 13.8 0.867
Sight 
threatening DR 50.8 23.2 12.9 13.1 0.721
NPDR 50.4 22.9 12.8 13.9 0.793 (compared with PDR)
Table 3. Haplogroup distribution (H, UK, JT, Other) according to DR phenotype.
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98 controls, OR 0.49, 96% CI 0.24–1.00, p = 0.05) and NPDR (85 cases, 98 controls, OR 0.31, 95% CI 0.13–0.78, 
p = 0.012). JT was nominally associated with NPDR (144 cases, 137 controls, OR 2.20, 95%CI 1.09–4.43, p = 0.027) 
and CSME (85 cases, 137 controls, OR 2.06, 95% CI 1.16–8.08, p = 0.024) These results should be treated with cau-
tion as the numbers are small and the association does not survive correction for multiple hypothesis testing.
Discussion
In our larger Caucasian sample, unlike earlier smaller studies, we found no significant associations between mito-
chondrial haplogroup and the presence of any DR, DME, nor more severe phenotypes such as PDR, CSME or 
sight-threatening DR (severe NPDR, CSME or PDR). This was true for analysis as a group or when stratified for 
type of diabetes, in spite of following the same methods of previous studies which found positive associations.
Estopinal et al. first demonstrated that haplogroups H1 and H2 (analysed collectively) and UK were associated 
with PDR when compared with NPDR in an American Caucasian sample (n = 197 NPDR, 195 PDR)11. Having 
either haplogroup H1 or H2 was a risk factor, while haplogroup UK was protective. Bregman et al. expanded 
from this initial study with 513 additional diabetic controls in the same databases (Vanderbilt Eye Institute and 
Vanderbilt University)12. They found that haplogroup H1 and H2, and UK were not associated with any incident 
DR compared with no DR. Using the same cohort, Mitchell et al. found duration of diabetes and HbA1c was 
significantly associated with PDR in haplogroups H1 and H2, but not UK, suggesting that mitochondrial hap-
logroups modify these clinical risk factors for the development of PDR in type 2 diabetes18. In a different study, 
Kofler et al. reported haplogroup T was significantly associated with any DR compared with no DR (12.1% vs 
5.1%; p = 0.046)13.
Inconsistent results are common in all areas of haplogroup association studies. For example Crispim et al. 
reported haplogroup cluster J/T was significantly associated with insulin resistance in a Caucasian Brazilian pop-
ulation19, but this was refuted by two other studies of Caucasian samples20,21. Challenges in interpreting mito-
chondrial association studies include differences in study design, case and control definitions, statistical analysis, 
population stratification, inadequate power and lack of replication22.
Different results could be due to different populations and study design, however in examining the demo-
graphics and distribution of the haplogroups, our group appears to be similar to the group from the Vanderbilt 
Eye Institute and Vanderbilt University. Both groups consist of Caucasian patients of European descent. We used 
the same criteria for selection of retinopathy cases and controls and the same statistical analyses. The most com-
mon haplogroups were H1 and H2, and UK; 73.3% in our study, compared with 68% in Bregman et al.'s study. 
As expected in both studies, age, diabetes duration, type of diabetes and HbA1c were strongly associated with 
increasing severity of DR.
An important reason why our results are different is because our study consisted of a much larger popula-
tion; 1124 diabetic retinopathy controls (no DR), 1161 NPDR cases and 650 PDR cases. Therefore our study 
has increased statistical power to identify any true associations. We were unable to replicate previously reported 
OR (95% CI)
P-value No DR vs Any DR
No DR vs 
NPDR No DR vs PDR No DR vs DME No DR vs CSME
No DR vs sight 
threatening NPDR vs PDR
Haplogroup H – Type 1 Diabetes
Haplogroup H 0.90 (0.58–1.40)P = 0.652
0.92 (0.57–1.48)
P = 0.718
0.95 (0.53–1.69)
P = 0.848
0.95 (0.52–1.77)
P = 0.881
0.79 (0.38–1.63)
P = 0.524
0.97 (0.58–1.63)
P = 0.918
0.98 (0.62–1.55)
P = 0.924
Sex (female) 1.34 (0.86–2.09)P = 0.199
1.30 (0.80–2.10)
P = 0.294
1.44 (0.79–2.62)
P = 0.231
1.43 (0.77–2.64)
P = 0.255
1.54 (0.78–3.17)
P = 0.243
1.43 (0.85–2.41)
P = 0.182
0.84 (0.53–1.33)
P = 0.453
Age 1.02 (1.0–1.03)P = 0.063
1.02 (1.0–1.04)
P = 0.011
0.99 (0.96–1.01)
P = 0.347
1.04 (1.02–1.06)
P = 3.81 × 10−3
1.03 (1.01–1.06)
P = 0.007
1.02(1.0–1.04)
P = 0.104
0.97 (0.95–0.99)
P = 0.001
Diabetes duration 1.13 (1.10–1.16)P < 0.0001
1.10 (1.07–1.13)
P < 0.0001
1.14 (1.11–1.19)
P < 0.0001
1.08 (1.04–1.11)
P < 0.0001
1.08 (1.04–1.12)
P < 0.0001
1.13 (1.10–1.17)
P < 0.0001
1.08 (1.06–1.11)
P < 0.0001
HbA1c 1.46 (1.26–1.70)P < 0.0001
1.38 (1.18–1.63)
P < 0.0001
1.54 (1.28–1.86)
P < 0.0001
1.57 (1.30–1.91)
P < 0.0001
1.49 (1.19–1.87)
P < 0.0001
1.52 (1.28–1.79)
P < 0.0001
1.25 (1.07–1.46)
P = 0.004
Hypertension 2.19 (1.30–3.68)P < 0.0001
1.61 (0.90–2.87)
P = 0.108
4.34 (2.24–8.41)
P < 0.0001
2.60 (1.34–5.07)
P = 4.85 × 10−3
2.61 (1.19–5.73)
P = 0.017
2.82 (1.57–5.05)
P = 0.001
2.21 (1.31–3.73)
P = 0.003
Haplogroup UK – Type 1 Diabetes
Haplogroup UK 0.80 (0.49–1.32)P = 0.391
0.68 (0.39–1.21)
P = 0.191
(0.53–1.91)
P = 0.989
0.65 (0.31–1.36)
P = 0.255
0.50 (0.21–1.24)
P = 0.136
0.88 (0.49–1.58)
P = 0.674
1.60 (0.93–2.75)
P = 0.087
Sex (female) 1.34 (0.86–2.09)P = 0.201
1.28 (0.79–2.08)
P = 0.311
1.44 (0.79–2.62)
P = 0.231
1.46 (0.79–2.70)
P = 0.231
1.53 (0.74–3.16)
P = 0.251
1.43 (0.85–2.42)
P = 0.177
0.84 (0.53–1.34)
P = 0.457
Age 1.02 (1.0–1.03)P = 0.064
1.02 (1.00–1.04)
P = 0.011
0.99 (0.96–1.01)
P = 0.351
1.04 (1.02–1.06)
P = 4.17 × 10−4
1.04 (1.00–1.06)
P = 0.007
1.02 (1.00–1.04)
P = 0.108
0.97 (0.95–0.99)
P = 0.001
Diabetes duration 1.13 (1.09–1.16)P < 0.0001
1.10 (1.06–1.13)
P < 0.0001
1.14 (1.11–1.19)
P < 0.0001
1.08 (1.04–1.11)
P < 0.0001
1.08 (1.04–1.12)
P < 0.0001
1.13 (1.10–1.17)
P < 0.0001
1.08 (1.06–1.11)
P < 0.0001
HbA1c 1.46 (1.26–1.70)P < 0.0001
1.39 (1.18–1.63)
P < 0.0001
1.54 (1.28–1.86)
P < 0.0001
1.56 (1.28–1.89)
P < 0.0001
1.47 (1.17–1.85)
P = 0.001
1.51 (1.28–1.79)
P < 0.0001
1.25 (1.07–1.46)
P = 0.004
Hypertension 2.22 (1.32–3.75)P = 0.003
1.67 (0.93–2.98)
P = 0.086
4.34 (2.23–8.42)
P < 0.0001
2.75 (1.40–5.41)
P = 0.003
2.86 (1.28–6.40)
P = 0.011
2.85 (1.58–5.13)
P = 4.80 × 10−4
2.27 (1.35–3.84)
P = 0.002
Table 4. Association of haplogroup H (H1 and H2) and UK with DR in type 1 diabetes: binary logistic 
regression adjusting for gender, age, diabetes duration and HbA1c.
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associations, suggesting that these previous association may be false. Smaller studies and sub analyses of pheno-
type groups lead to a higher risk of type 1 errors23. Our larger study size allowed us to analyse other phenotypes 
such as DME and CSME, as well as to separately analyse less common haplogroups such as JT, and K separate 
from UK. The only statistically significant results we found were haplogroup K was nominally associated with 
any DR, and haplogroup JT was nominally associated with NPDR and CSME. As the numbers were small in 
these comparisons and the result does not survive multiple hypothesis testing, this is likely to be type 1 error. 
Haplogroup K was not a common haplogroup in the previous two studies and is not implicated in diabetes and 
other associated diseases. Kofler et al. reported haplogroup T was significantly associated with any DR but this 
study also had a much smaller sample size (149 with any DR and 78 with no DR)13. As noted in our results, we were 
unable to separately analyse haplogroup T due to genotyping failure, and so direct comparison to Kofler et al.’s 
study could not be made.
In addition to study size, strengths of this study include the inclusion of both T1DM and T2DM subjects from 
multiple sites, rigour of retinopathy status characterisation, wide range of levels of DR and use of the same haplo-
typing methods and statistical analyses as previous studies so comparisons could be made.
The haplotyping method we utilized from previous studies has an important limitation. SNPs chosen to rep-
resent the H haplogroup (rCRS position 3010 and 1438) only identify haplogroups H1 and H2. Therefore 7 other 
major subtypes of haplogroup H were not analysed. In our study, one SNP completely failed genotyping (rCRS 
11812, determination of haplogroup T2) and therefore we could not analyse haplogroup T separately. Another 
4 SNPs had a 2% failure rate, and this could have contributed to the percentage of samples with haplogroup R (a 
major clade consisting of H, J, T, and UK). We chose our Caucasian sample based on participants self-identifying 
as Caucasian, but a small number had non-Caucasian haplogroups (for example haplogroup A, B, C, L, M, N and 
Q). Some of the 22 SNPs chosen for haplogroup determination are also found in other ethnic populations (for 
example rCRS position 3197 determines U5 but also L3e3 which is found in Asian populations). Therefore, all 
samples with a non-Caucasian haplogroup were removed to minimize any confounding effect and reduce popu-
lation stratification.
We recognise that even larger studies and studies in different ethnic groups, particularly those at high risk of 
diabetic retinopathy, are desirable. We only studied 7 haplogroups, while the human mitochondrial phylogenetic 
tree consists of hundreds of haplogroups. The hypothesis that variations in mitochondrial genetics contribute 
to DR risk is logical given the role that the mitochondria play in oxidative stress7 and their presence in the ret-
ina24. Mitochondrial DNA are inherited completely from the maternal line, unlike nuclear DNA which has equal 
maternal and paternal contributions25. Risk of T1DM in the offspring varies by parental status; being two-fold 
lower if the mother has T1DM rather than the father26. Epidemiology studies show that certain ethnicities are 
at greater risk of DR such as people of Asian, African and Indigenous ethnic groups27. Complex biological and 
environmental factors explain this observation, and mitochondrial genetics could also play a role, but this has 
not been studied.
OR, 95% CI, P 
value
No DR vs Any 
DR No DR vs NPDR No DR vs PDR No DR vs DME
No DR vs 
CSME
No DR vs sight 
threatening NPDR vs PDR
Haplogroup H – Type 2 Diabetes
Haplogroup H 1.03 (0.83–1.28)  P = 0.777
1.07 (0.85–1.34)  
P = 0.571
0.92 (0.66–1.27)  
P = 0.612
1.04 (0.80–1.34)  
P = 0.780
0.91 (0.69–1.21)  
P = 0.521
1.04 (0.81–1.32)  
P = 0.763
0.93 (0.69–1.23) 
P = 0.598
Sex (female) 0.75 (0.60–0.93)  P = 0.008
0.76 (0.60–0.96)  
P = 0.019
0.70 (0.50–0.97)  
P = 0.033
0.87 (0.67–1.12)  
P = 0.270
0.87 (0.65–1.15)  
P = 0.328
0.79 (0.63–1.01)  
P = 0.064
0.95 (0.70–1.27) 
P = 0.711
Age 0.98 (0.97–0.99)  P < 0.0001
0.99 (0.98–1.0)  
P = 0.016
0.96 (0.94–0.97)  
P < 0.0001
0.98 (0.97–0.99)  
P = 4.81 × 10−4
0.98 (0.97–0.99)  
P = 0.002
0.97 (0.96–0.99)  
P < 0.0001
0.97 (0.96–0.98) 
P < 0.0001
Diabetes duration 1.09 (1.08–1.11)  P < 0.0001
1.08 (1.07–1.10)  
P < 0.0001
1.12 (1.10–1.15)  
P < 0.0001
1.10 (1.08–1.12)  
P < 0.0001
1.10 (1.08–1.12)  
P < 0.0001
1.11 (1.09–1.12)  
P < 0.0001
1.04 (1.02–1.06) 
P < 0.0001
HbA1c 1.37 (1.27–1.48)  P < 0.0001
1.33 (1.22–1.44)  
P < 0.0001
1.50 (1.34–1.67)  
P < 0.0001
1.45 (1.32–1.58)  
P < 0.0001
1.44 (1.30–1.60)  
P < 0.0001
1.45 (1.33–1.58)  
P < 0.0001
1.15 (1.06–1.26) 
P = 0.001
Hypertension 0.96 (0.74–1.24)  P = 0.742
0.94 (0.71–1.25)  
P = 0.681
0.96 (0.65–1.43)  
P = 0.846
0.77 (0.57–1.04)  
P = 0.092
1.06 (0.74–1.51)  
P = 0.758
0.83 (0.62–1.11)  
P = 0.208
1.01 (0.71–1.44) 
P = 0.943
Haplogroup UK – Type 2 Diabetes
Haplogroup UK (0.77–1.29)  P = 0.981
0.98 (0.74–1.29)  
P = 0.863
1.13 (0.76–1.67)  
P = 0.541
1.08 (0.80–1.46)  
P = 0.630
1.13 (0.81–1.59)  
P = 0.464
1.03 (0.77–1.38)  
P = 0.849
1.07 (0.75–1.51) 
P = 0.714
Sex (female) 0.75 (0.60–0.93)  P = 0.008
0.76 (0.60–0.95)  
P = 0.018
0.70 (0.50–0.97)  
P = 0.034
0.87 (0.67–1.12)  
P = 0.267
0.87 (0.66–1.16)  
P = 0.348
0.79 (0.62–1.01)  
P = 0.063
0.95 (0.70–1.27) 
P = 0.712
Age 0.98 (0.97–0.99)  P < 0.0001
0.99 (0.98–1.0)  
P = 0.016
0.96 (0.94–0.97)  
P < 0.0001
0.98 (0.97–0.99)  
P = 4.73 × 10−4
0.98 (0.97–0.99)  
P = 0.002
0.97 (0.96–0.99)  
P < 0.0001
0.97 (0.96–0.98) 
P < 0.0001
Diabetes duration 1.09 (1.08–1.11)  P < 0.0001
1.08 (1.07–1.10)  
P < 0.0001
1.12 (1.10–1.15)  
P < 0.0001
1.10 (1.08–1.12)  
P < 0.0001
1.10 (1.08–1.12)  
P < 0.0001
1.11 (1.09–1.12)  
P < 0.0001
1.04 (1.02–1.06) 
P < 0.0001
HbA1c 1.37 (1.27–1.48)  P < 0.0001
1.33 (1.22–1.44)  
P < 0.0001
1.50 (1.34–1.67)  
P < 0.0001
1.45 (1.32–1.58)  
P < 0.0001
1.44 (1.30–1.60)  
P < 0.0001
1.45 (1.33–1.58)  
P < 0.0001
1.15 (1.06–1.26) 
P = 0.001
Hypertension 0.96 (0.74–1.25)  P = 0.746
0.95 (0.72–1.25)  
P = 0.695
0.96 (0.64–1.43)  
P = 0.839
0.77 (0.57–1.04)  
P = 0.091
1.05 (0.74–1.50)  
P = 0.772
0.83 (0.62–1.11)  
P = 0.207
1.01 (0.71–1.44) 
P = 0.953
Table 5. Association of haplogroup H and UK with DR in type 2 diabetes: binary logistic regression adjusting 
for gender, age, diabetes duration and HbA1c.
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Mitochondrial haplogroup is not a specific marker for mitochondrial genetic variability. A haplogroup con-
sists of many genetic variants that are inherited together. Therefore, if there are specific mitochondrial variants 
that contribute to DR, these cannot be studied effectively. Single nucleotide polymorphisms in mitochondria 
cause diseases such as Leber hereditary optic neuropathy, and in complex diseases such as diabetes and cancer, 
it is increasingly recognised that small mitochondrial defects could lead to subtle bioenergetics alterations with 
major clinical implications28. Specific mitochondrial variants that have been studied for DR include mutations in 
UCP2 and Mn-SOD genes4.
Few studies have demonstrated whether mitochondrial haplogroup directly affects mitochondrial function. 
Fang et al. recently reported lower respiratory chain complex activity in haplogroup N9a compared with D4j, 
G4a2 and Y1, using transmitochondrial technology29. Mueller et al. reported mitochondrial haplogroup T cell 
cybrids had a higher survival rate than haplogroup H cybrids under oxidative stress conditions such as when 
challenged with hydrogen peroxide30. Haplogroup K cybrids showed different gene expression levels compared 
with H cybrids after amyloid-beta toxicity31. Untreated retinal cell cybrids of H and J haplogroups also showed 
different gene expression and methylation status32. Future studies and techniques designed to explore the mito-
chondria genome in better detail than currently available can help us understand whether mitochondrial genetics 
contribute to DR risk33.
Conclusion
In contrast to previous studies, our much larger study found no association between the major European mito-
chondrial haplogroup H1, H2, UK, and DR phenotypes in either type 1 or type 2 diabetes. No significant asso-
ciations were found for different severities of DR and DME, or other subsets of mitochondrial haplogroups that 
were analysed by this study.
Data Availability
The dataset generated for analysis in the current study is available under a CC BY-NC-ND license at: https://doi.
org/10.25957/5c060cbdb9162.
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